Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
SYRE
Stock Latest News
Ratings
Positive Phase 2 Data from APGE Bolsters Spyre Therapeutics’ Strategy and Stock Appeal
18d ago
SYRE
Premium
Ratings
Spyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
1M ago
SYRE
Premium
Ratings
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
1M ago
SYRE
Premium
Ratings
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
1M ago
SYRE
Premium
Company Announcements
Spyre Therapeutics Announces Positive Phase 1 Results
1M ago
8K
SYRE
Premium
The Fly
Spyre Therapeutics reports positive interim Phase 1 results for TL1A antibodies
1M ago
SYRE
Premium
Ratings
Spyre Therapeutics’ Promising TL1A Program and Undervalued Potential in IBD Market
2M ago
SYRE
Premium
Company Announcements
Spyre Therapeutics Holds Annual Stockholders Meeting
2M ago
8K
SYRE
Premium
Ratings
Strong Financial Position and Promising Clinical Developments Position Spyre Therapeutics for Success
3M ago
SYRE
Premium
Ratings
Spyre Therapeutics: Promising Developments in IBD Treatment with Biologics-Based Therapies
3M ago
SYRE
Premium
Ratings
Promising Outlook for Spyre Therapeutics: Buy Rating Backed by Strong Financials and Positive Clinical Progress
3M ago
SYRE
Premium
Ratings
Promising Potential and Strategic Advancements Justify Buy Rating for Spyre Therapeutics
3M ago
SYRE
Premium
Company Announcements
Spyre Therapeutics Reports Q1 2025 Financial Results
3M ago
SYRE
Premium
Ratings
Spyre Therapeutics: Promising Future with Innovative IBD Treatments and Strategic Advancements
3M ago
SYRE
Premium
The Fly
Spyre Therapeutics reports Q1 EPS (60c), consensus (84c)
3M ago
SYRE
Premium
Pre-Earnings
SYRE Upcoming Earnings Report: What to Expect?
3M ago
SYRE
Premium
The Fly
Spyre Therapeutics’ SPY001 shows efficacy in two poster presentations
3M ago
SYRE
Premium
The Fly
Leerink bullish on Spyre Therapeutics, initiates with an Outperform
4M ago
SYRE
Premium
The Fly
Spyre Therapeutics initiated with an Outperform at Leerink
4M ago
SYRE
Premium
Ratings
Promising Outlook for Spyre Therapeutics’ SPY003: Potential Game-Changer in IBD Treatment
4M ago
SYRE
Premium
The Fly
Spyre Therapeutics says first patient dosed in Phase 1 trial of SPY003
4M ago
SYRE
Premium
Ratings
Strategic Potential of Spyre Therapeutics in Combination Therapies for Inflammatory Diseases
4M ago
SYRE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
